Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITION first-line combination therapy study in pulmonary arterial hypertension
NL-OMON39521Phase 4Active, not recruiting
- Sponsor
- GSK
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ambrisentan and tadalafil in pulmonary arterial hypertension (PAH) (3 arms), sponsored by GSK. Primary endpoint: Time to first clinical failure of treatment. Started Jan 2011; status: active, not recruiting.
02
Drugs
ambrisentantadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON39521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39521.